^
Association details:
| Biomarker: | HER-2 overexpression |
|---|---|
| Cancer: | Hormone Receptor Negative Breast Cancer |
| Drug: | Herceptin (trastuzumab) (HER2 inhibitor) + lapatinib (EGFR inhibitor, HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
Tyverb is indicated for the treatment of patients with breast cancer, whose tumours overexpress HER2 (ErbB2):...in combination with trastuzumab for patients with hormone-receptor-negative metastatic disease that has progressed on prior trastuzumab therapy or therapies in combination with chemotherapy...
